2 For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to surgery is conditionally recommended. This conditional recommendation was changed from the prior guideline. For the previous guideline, while the short serum half-life of tofacitinib was known, concern for a longer duration of the immune effect prompted the recommendation to withhold tofacitinib for 7 days prior to surgery. The new recommendation was informed by trial data demonstrating rapid increases in disease activity after interrupting tofacitinib therapy, suggesting a rapid reversal of the immunosuppressive effects, so the recommendation was changed to withhold tofacitinib for 3 days prior to surgery For patients with SLE (not severe) undergoing THA or TKA, withholding the current dose of mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, mizoribine, or tacrolimus 1 week prior to surgery is conditionally